Avaliação Citotóxica da MAMMEA A/BB em linhagens de células de glioma

Abstract

Glioblastoma is the most aggressive form of gliomas and the available therapeutic resources are limited and involve surgical resection, radiotherapy and chemotherapy. The search for more effective and less aggressive pharmacological alternatives places mammea A/BB under analysis. This plant metabolite is found in the bark of roots of the botanical family Calophyllaceae, of the genus Kielmeyera. The objective of this study was to evaluate the cytotoxic potential of mammea A/BB in human glioblastoma U251 and C6 rat glioma cells. The pharmacological action of mammea A/BB was tested in both strains by cell viability assays by MTT, migration test, cariopnosis quantification and p-glycoprotein expression.The effect of the drug on normal murine astrocytic cells and a comparison of cell viability between the test drug and the first-line chemotherapy, temozolomide, were also analyzed. The experiments showed that the U251 and C6 cell lines had a concentration dependent sensitivity to mammae A/BB and resistance to temozolomide in the concentration range of 2 μM to 200 μM in all the analyzed samples. The concentrations of 27 ± 2.31 μM and 56.85 ± 14.17 μM of mammea A/BB were able to inhibit the cell population in 50% in the lines U251 and C6, respectively, as well as the migratory potential of these lines. The test drug shows no cytotoxic action on murine astrocyte cells. Pinocytic nuclei were found in greater quantity in the treatment with mammea A/BB when compared to the control and DMSO conditions. Mammea A/BB showed no significant difference in the induction of P-glycoprotein expression. The results indicate a potential pharmacological action in the induction of cytotoxicity of the drug in tumor cell types and non-cytotoxic in the normal cells evaluated.